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H I G H L I G H T S
 Cysteinyl-leukotrienes accumulated during Concanavalin A-induced mouse liver injury.
 5-LO upregulation triggered the autoimmune reaction after Concanavalin A challenge.
 Seven upregulated and two downregulated miRs were found related to hepatotoxicity of Concanavalin A.
 MiR-674-5p negatively regulated 5-LO in hepatic cells with IL-6 or TNF-a presence.
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A B S T R A C T
Autoimmune hepatitis is characterized, in part, by the pathways involving cysteinyl-leukotriene
metabolites of arachidonic acid, the dynamics of which remain unclear. Here, we explored post-
transcriptional regulation in the 5-lipoxygenase (5-LO) pathway of arachidonic acid in a Concanavalin A
(Con A) induced mouse model. We found that Con A administration lead to 5-LO overexpression and
cysteinyl-leukotriene release in early hepatic injury, which was attenuated by cyclosporin A
pretreatment. Subsequent microarray and qRT-PCR analysis further showed that microRNA-674-5p
(miR-674-5p) displayed a signiﬁcant decrease in expression in Con A-damaged liver. Noting that miR-
674-5p harbors a potential binding region for 5-LO, we further transfected hepatic cell lines with
overexpressing miR-674-5p mimic and discovered a negative regulating effect of miR-674-5p on 5-LO
expression in the presence of IL-6 or TNF-a. These ﬁndings suggest that miR-674-5p might be a negative
regulator in 5-LO mediated autoimmune liver injury, representing a compelling avenue towards future
therapeutic interventions.
ã 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Acute hepatitis is a disease characterized by the presence of
inﬂammatory cells in the liver, and has both a high global incidence* Corresponding author at: State Key Laboratory for Diagnosis and Treatment of
Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of
Infectious Diseases, The First Afﬁliated Hospital, College of Medicine, Zhejiang
University, 79 Qingchun, Hangzhou 310003, China.
E-mail address: ljli@zju.edu.cn (L. Li).
http://dx.doi.org/10.1016/j.toxlet.2016.06.010
0378-4274/ã 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access a
nd/4.0/).and a high mortality. (MacLachlan and Cowie, 2015). The
underlying mechanisms of the autoimmune and inﬂammatory
processes involved in acute hepatitis progression remain unclear.
The Concanavalin A (Con A)-induced murine model mimics the
context of acute viral hepatitis using activated CD4+ T cell
mediated hepatocyte dysfunction (Czaja, 2010; Tiegs et al.,
1992). T cells and macrophages inﬁltration followed by pro-
inﬂammatory cytokine, such as tumor necrosis factor alpha (TNF-
a), interferon-gamma (IFN-g), interleukin (IL)-6 and/or IL-10,
secretion activates inﬂammatory mediator signaling cascades and
lead to hepatic cellular pathological response (Wang et al., 2006).rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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mouse livers to create a clearer picture of the inﬂammatory and
autoimmune responses that characterize acute hepatitis, which
will be useful for creating more effective viral intervention
therapies in the future.
When liver damage is initiated, the initial burst of cytokines and
chemokines produced by resident leukocytes, including TNF-a and
IL-6, along with cellular and extracellular contents released by the
damaged tissue, lead to rapid tissue dysfunction (Bentzinger et al.,
2013; Brigitte et al., 2010; Wang and Thorlacius, 2005). Concur-
rently, arachidonic acid (AA) is metabolized into cysteinyl-
leukotrienes (Cys-LTs) and prostaglandin E2 (PGE2) via the 5-
lipoxygenase (5-LO) pathway and the cyclooxygenases 2 (COX2)
pathway, respectively (Funk, 2001). Cys-LTs are a type of
ubiquitous inﬂammatory mediators, whose formation is largely
dependent on the activation of 5-LO pathway (Chang et al., 2014;
Martínez-Clemente et al., 2010; Titos et al., 2005). Cys-LTs actively
participate in regulating inﬂammatory reaction in autoimmune
hepatitis (Quiroga and Prieto, 1993), and can aggravate liver
damage, especially by increasing inward calcium, causing capillary
contraction or reducing glutathione exhaustion (Hohmann et al.,
2013; Shimada et al., 1998). Although changes in 5-LO expression
have been discovered in the Con A-induced early hepatic injury
models, the precise regulating mechanisms and subsequent effects
remain unclear (Busch et al., 2015). Here, we explore the
expressions of 5-LO and its chaperone 5-lipoxygenase  activating
protein (FLAP), as well as the involvement of corresponding
cytokines in the initial phase of Con A treatment. In particular, we
use pretreatment with immunosuppressive agents to elucidate
speciﬁc targets involved in regulating the 5-LO pathway.
MicroRNAs (miRNAs) are small non-coding RNAs that can
regulate gene production through the degradation of target mRNAs
(Bartel, 2004). MiRNAs are cleaved from 50 to 70 nucleotide single-
stranded pre-miRNAs or double-stranded RNAs by the ribonucle-
ase III enzyme Dicer (Bernstein et al., 2001). Functional miRNAs
play crucial roles in various vital biological processes, and
deregulation of miRNAs results in pathological conditions (Ban-
diera et al., 2015; Xie et al., 2014; Zhao et al., 2014). The
dysregulation of miRNAs, such as miR-19a-3p and miR-125b-5p,
has been implicated in hepatic injury (Busch et al., 2015).
Importantly, during the initiation and progression of inﬂamma-
tion, 5-LO not only functions as a metabolic enzyme for AA, but also
interacts with Dicer. By binding Dicer to the C-terminus, the
catalytic activity of 5-LO is markedly enhanced (Dincbas-Renqvist
et al., 2009). Thus, the regulation of 5-LO in the post-transcription
phase could play an integral role in Cys-LTs production.
In this study, we ﬁnd that 5-LO acts as a key enzyme for cys-LTs
generation in Con A-induced mouse immunological liver injury.
Furthermore, we demonstrated that miR-674-5p negatively
regulated 5-LO expression in the acute hepatic inﬂammation.
Our results create a clearer picture of the roles of miRNAs in
regulating AA metabolism and innate immune related liver injury
via 5-LO signaling activation, and suggest targets for future
interventional therapies.
2. Materials and methods
2.1. Animals
Eight-week-old male pathogen-free BALB/c mice were obtained
from the Experimental Animal Center, Zhejiang University,
Hangzhou, China (Grade II, Certiﬁcate SCXK 2008-0016), All mice
were maintained for at least 6–7 days under a 12-h light/dark cycle
in a humidity and temperature-controlled, speciﬁc-pathogen-free
environment in autoclaved cages. The experiments were con-
ducted under the Guide for the Care and Use of Laboratory Animals,Eighth Edition (2011), and all experiments were approved by the
Experimental Animal Care and Use Committee of Zhejiang
University (Ethics Code: No. ZJUFH2015195).
2.2. Con A challenge and cyclosporin A pretreatment
Mice were intravenously treated with a dose of 20 mg/kg of Con
A (type IV, Sigma, St. Louis, MO, USA) (Streetz et al., 2001). Fourteen
mice were intravenously pretreated with 150 mg/kg of cyclosporin
A (CsA) (Sandoz, Switzerland) at both 15 h and 1 h before Con A
administration (Tiegs et al., 1992), while seven mice received the
same volume saline injection at the same time points. The mice
were sacriﬁced for blood and liver collection at 0 (normal), 1, 2, 4
and 8 h after Con A injection or 0, 2 and 8 h after CsA/Con A
treatment. Blood was taken for serum transaminase and cytokine
measurements. Liver tissue was in part ﬁxed for histologic
examination, while the rest was frozen in liquid nitrogen and
stored at 80 C for inﬂammatory mediator assay and RNA or
protein isolation.
2.3. Histological evaluation and serum transaminase activities
Liver tissues were ﬁxed in 10% (v/v) neutral-buffered formalin,
embedded in parafﬁn, sliced in 5-mm thin sections and
subsequently evaluated by hematoxylin-eosin (H&E) staining.
Each section was examined for the evidence of acute inﬂammation
at the indicated times, including congestion, hepatocyte swelling
and inﬂammatory cell inﬁltration. Serum alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) activity was quanti-
tated as units per liter by an automated enzyme assay procedure
using Hitachi 7600 automated biochemistry analyzer (Hitachi,
Tokyo, Japan).
2.4. ELISA and radioimmunoassay
Serum IL-6 and TNF-a were assessed by ELISA kits (R&D system,
Minneapolis, MN, USA). Cys-LTs in the supernatant of liver tissue
homogenate were measured by enzyme-linked immunosorbent
assay using an ELISA kit (Cayman Chemical, Ann Arbor, MI, USA),
and PGE2 in the supernatant were assessed by a radioimmunoassay
kit (Suzhou University, Suzhou, PRC), respectively, according to the
manufacturer’s instruction.
2.5. Cell culture
Hepa1-6 and HepG2 cell lines were obtained from the China
Center for Type Culture Collection (Purchase No: 22008, Shanghai,
PRC) and maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum (Gibco, Gaithersburg,
MD, USA) at 37 C and humidiﬁed with 5% (v/v) CO2 in an incubator.
2.6. Plasmid and transfection
The miR-674-5p mimic and its respective control (scramble)
were designed and synthesized (RiboBio, Guangzhou, PRC).
Transfection was carried out using Lipofectamine 3000 reagent
(Invitrogen, Carlsbad, CA, USA). Brieﬂy, 5 105 cells were seeded
into each well of 6-well plates, and given serum-free medium for
24 h. The miR-674-5p mimic and its respective control (50 nM)
were introduced to the cells with 5 ml Lipofectamine 3000 in
serum-free medium. The miR-674-5p mimic and its negative
control were designed and synthesized (RiboBio, Guangzhou, PRC)
as follows: miR-674-5p mimic sense: 50-gcacugagaugggaguggu-
gua-30; negative control sense: sequences without homologous to
miR-674-5p. Hepa1-6 and HepG2 Cells were challenged by IL-6
(50 ng/ml) or TNF-a (25 ng/ml) for 0 (normal), 1, 2 and 4 h after
Fig.1. Con A-induced mice liver injury. (A) Mice were injected with 20 mg/kg of Con
A or saline and sacriﬁced at indicated time points. The insets are magniﬁcation of
which arrows point (HE staining, bar = 100 mm and inset bar = 25 mm). (B) Serum
AST and ALT levels elevated in Con A treated mice (Con A mice). (C) IL-6 and TNF-a
levels in serum of Con A mice ﬂuctuated with time. (D) PGE2 and CysLTs displayed
distinguished patterns of alteration. PGE2 variated gradually, while CysLTs gained
peak level within 1 h, then fell down to a moderately signiﬁcant increase (Data are
represented as mean  SD. *P < 0.05 and **P < 0.01. n = 6).
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indicated time points after transfection.
2.7. Microarray proﬁling and bioinformatic predictions
RNA samples were extracted from livers of mice treated by Con
A or saline, and then labeled and hybridized on the miRCURYTM
LNA Array (v.16.0, Exiqon, Denmark). MiRNA microarray analysis
was performed by KangChen Bio-tech (Shanghai, China). To
identify differentially expressed miRNAs with statistical signiﬁ-
cance, we performed a volcano plot ﬁltering. The threshold to
screen dysregulated miRNAs is fold change 1.5 and P < 0.05.
Dysregulated miRNAs were clustered to the two-way hierarchical
heat map.
The target gene of miRNAs was predicted based on (1) the
overlap of prediction results by four out of ﬁve target prediction
tools, including TargetScan (Agarwal et al., 2015), PicTar (Krek
et al., 2005), miRanda (Betel et al., 2008), DIANA-microT (Para-
skevopoulou et al., 2013) and miRDB (Wong and Wang, 2015)
(combining machine-learning, alignment, interaction energy and
statistical tests in order to minimize false positives), and (2)
evidence from previous microarray analysis on the expression of
these targets (Chen et al., 2010). Potential target genes were cross-
checked with two expression proﬁles in Con A-induced mouse
models from public database (Chen et al., 2010; Fujita et al., 2015).
BLASTN was employed to retrieve the counterparts of miRNAs
across species (Altschul et al., 1997).
2.8. RNA isolation and qRT-PCR
Total RNA was harvested using TRIzol (Invitrogen, Carlsbad, CA,
USA) and miRNeasy mini kit (QIAGEN, Valencia, CA, USA) according
to manufacturer’s instructions. Premature sequences of screened
miRNAs were retrieved from miRBase and applied to design hair-
pin structured primers. The ampliﬁed products were quantitated
by SYBR Premix Ex Taq (Takara, Tokyo, Japan) on ABI PRISM 7900
system (Applied Biosystems, Foster, CA, USA). GAPDH and U6
snRNA were used as internal controls, respectively (detailed
information is available in Supplementary Tables 1 and 2).
2.9. Western blotting
Total protein extraction and Western blotting were performed
as previously described (Yang et al., 2011). Antibodies to 5-LO and
FLAP were purchased from Cell Signaling Technology (Danvers,
MA, USA), and NOVUS (Littleton CO, USA), respectively (detailed
information is available in Supplementary Table 3).
2.10. Statistical analysis
Unless otherwise indicated, the results are reported as the
mean  SD from at least three independent experiments. Statistical
differences were determined by the independent group Student’s t
test. Analyses were performed using GraphPad 5 (GraphPad
Software, San Diego, CA, USA) or home-made R scripts.
3. Results
3.1. Con A-induced Cys-LTs enhancement in mouse acute liver injury
After Con A injection, we found that liver tissue displayed
congestion, hepatocyte swelling and inﬂammatory cell inﬁltration
within 2 h (Fig. 1A). Notably, both serum AST and ALT activities
signiﬁcantly increased at 1 h and 2 h, and reached peak levels as
2079  555 U/L (AST) and 1822  489 U/L (ALT) at 8 h (Fig. 1B),
indicating hepatic function injured within 2 h following Con Ainjection. Serum IL-6 and TNF-a levels robustly increased and
peaked as early as 1 h after Con A challenge, (Fig. 1C), suggesting
that IL-6 and TNF-a was involved in the hepatic injury process as
early as 1 h after Con A treatment. Bearing in mind that Cys-LTs
content was signiﬁcantly elevated at the same time, and reached a
plateau about 4-fold of the basal level until 2 h, we argued that Il-6
and TNF-a probably are involved in triggering Cys-LTs production.
In contrast, PGE2 levels showed almost no increase (Fig. 1D),
implying that the 5-LO pathway of AA metabolism is an integral
component in early phase in Con A-induced liver injury.
3.2. 5-LO contributed to Con A-induced acute liver pathological
process
Immune inhibitor CsA was further used to determine the
pathological targets and possible mechanisms of injury in Con A-
induced injury to mouse liver. CsA pretreatment signiﬁcantly
reduced serum ALT levels compared with that found in mice
Fig. 3. Proﬁling and validation of dysregulated miRNAs in Con A injured mouse
liver. (A) Hierarchical clustering indicated dysregulated miRNAs between livers
from two groups. (B) qRT-PCR assay further validated selected miRNA expression
(Data are shown as mean  SD. n = 8).
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decreased serum Cys-LTs levels as well (Fig. 2B). Notably, ELISA
assay revealed that CsA pretreatment signiﬁcantly reduced serum
IL-6 and TNF-a levels induced by Con A challenge (Fig. 2C and D).
Furthermore, Western blotting analysis demonstrated that CsA
signiﬁcantly suppressed the 5-LO overexpression triggered by Con
A, while expression of the chaperone protein FLAP in the 5-LO
pathway was unaffected (Fig. 2E). Reduced levels of 5-LO
expression were also conﬁrmed by qRT-PCR (Fig. 2F). These results
imply that 5-LO plays a key role in Cys-LTs generation in the Con A-
induced liver pathological process, including both inﬂammatory
and immune responses. Based on these results, we then focused
our investigation on the underlying mechanisms of Con A-induced
liver injury in the ﬁrst 2 h after Con A challenge.
3.3. Dysregulated miRNAs in Con A injured mouse liver
Microarray analysis showed that 2189 miRNAs were signiﬁ-
cantly changed (1288 upregulated and 901 downregulated,
detailed data available online http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token=ezkleskubhwdbuz&acc=GSE76345). Heat
map represented miRNA microarray analysis of livers challenged
with Con A as compared with negative control (Fig. 3A). Among
them, miR-674-5p was the most markedly downregulated and
reached 7.14-fold (2.86-fold conﬁrmed by qRT-PCR shown in
Fig. 3B). Other signiﬁcantly altered microRNAs were demonstrated
in Supplementary Table 4.
3.4. 5-LO was a candidate target of miR-674-5p
Multiple tools were employed to explore the miRNA binding of
miR-674-5p, and the data suggested a potential binding of miR-
674-5p to the 30 UTR of 5-LO, indicating that 5-LO is a promising
candidate for targeting by miR-674-5p. Minimum free energy
calculation of mmu-miR-674-5p/mmu-5-LO binding from RNAhy-
brid was found to be as low as 30.4 kcal/mol (Fig. 4A).Fig. 2. CsA attenuated the pro-inﬂammatory effects of 5-LO in Con A-induced liver injur
elevation was inhibited by CsA pretreatment. (C, D) IL-6 and TNF-a levels elevated by C
differed after CsA/Con A treatment. Elevation of 5-LO protein was mitigated whereas
attenuation by CsA pretreatment. (Data are expressed as mean  SD and means are conne
of difference between Con A and CsA/Con A groups, n = 7.Furthermore, BLASTN results indicated that mouse and rat miR-
674-5p shared the same seeding region, though no counterpart
was found in the human genome. However, multiple sequences
alignment of 5-LO’s suggested that the binding sites of mmu-miR-
674-5p were conserved across mouse, rat and human (Fig. 4B).
Overall, in silico analysis suggested that the binding between 5-LO
and miR-674-5p was conserved across mammal genomes. Wey of mice. (A) Serum ALT elevation was alleviated after CsA pretreatment. (B) CysLTs
on A were relieved by preconditioning of CsA. (E) Protein levels of 5-LO and FLAP
 FLAP remained steady by CsA administration (F) mRNA levels of 5-LO displayed
cted by lines. *P < 0.05 and **P < 0.01 below the time point indicated the signiﬁcance
Fig. 4. 5-LO was a potential target of miR-674-5p. (A) RNAhybrid prediction showed
mmu-miR-674-5p potentially binds to the 30 UTR of 5-LO, and the minimum free
energy is 30.4 kcal/mol. (B) Database retrieved homologous sequences to mmu-
miR-674-5p/mmu-5-LO pair. The counterpart of miR-674-5p was missing in the
human genome, but rat and human 5-LOs preserved most part of the seeding region
of mmu-miR-674-5p.
Fig. 5. 5-LO expression was negatively regulated by miR-674-5p in hepatic cell
lines. (A, B) Western blot assay exhibited 5-LO expression in Hepa 1–6 cells was
affected by mimic of miR-674-5p at 1 h and 4 h post IL-6 and TNF-a stimulation,
respectively. (C) Schematic illustration of the miR-674-5p mediated 5-LO regulation
in Con A-induced liver injury.
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verify the post-transcriptional regulating effect of miR-674-5p on
5-LO.
3.5. 5-LO expression is negatively regulated by miR-674-5p in hepatic
cell lines
To further conﬁrm the regulating role of miR-674-5p/5-LO axis,
we assessed the expression levels of 5-LO in two hepatocellular
carcinoma cell lines. Downregulation of 5-LO was evaluated in miR-
674-5p mimic transfected cells incubated with IL-6 or TNF-a, using
scramble as a control. For murine cell line Hepa 1–6, the miR-674-5p
mimic decreased 5-LO expression at 1 h after IL-6 challenge (Fig. 5A)
and 4 h after TNF-a stimulation (Fig. 5B). In contrast, such early
response was only found at 4 h after IL-6 challenge in HepG2 cell line
(Fig. S1). These results indicated that miR-674-5p can negatively
regulate 5-LO expression in the presence of IL-6 or TNF-a.
4. Discussion
In this study, we demonstrate that 5-LO is a key enzyme
contributing to cys-LTs generation in the autoimmune process of
Con A-induced mouse liver injury. Microarray proﬁling and qRT-
PCR of miRNAs indicate that Con A-induced mouse liver injury is
further characterized by signiﬁcant downregulation. Moreover, we
ﬁnd that the overexpression of miR-674-5p leads to an inversely
expressed pattern of 5-LO in hepatic cell lines, suggesting that miR-
674-5p has a post-transcriptional regulating effect on 5-LO.
Con A administration results in immune-mediated liver injury
similar to that found in acute hepatitis, and cytokines are
important to determining the outcome of liver failure in this
model. In particular, research indicates that TNF-a and IFN-g
contribute directly to hepatocyte damage (Streetz et al., 2001).
However, the intracellular pathways of cytokines cascades and the
initial events in Con A induced liver injury remain poorly
understood. TNF-a, IFN-g and IL-6 are early phase cytokines,
and their genes expression reaches peak levels in liver tissue
within 1 h after Con A challenge (Lavon et al., 2003). Importantly,
anti-IFN-g treatment blocks liver cell damage, but not inﬁltration
of CD4-positive and CD45-positive cells after Con A injection.
Therefore, a clearer picture of the events involved in IFN-
g-independent liver injury will be integral to better understanding
the novel mechanism of immune-mediated liver damage after Con
A challenge. The activation of TNF-a and IFN-g-dependentintracellular pathways occurs prior to the inﬂux of immune-
activated cells into the liver (Streetz et al., 2001), and these two
pathways exhibits different patterns during Con A induced liver
injury (Jakubowski et al., 2015). Furthermore, a synthetic
cannabinoid derivative acting as an immune-modulator displays
the dual role of regulating IFN-g and IL-6 gene expression during
the early phase after Con A injection, promoting Ifn-g expression
and inhibiting Il-6 expression (Lavon et al., 2003). Moreover, Con A-
induced T-cell hepatitis is initiated and tightly controlled by
interactions between multiple cell types, a variety of cytokines,
and their downstream signaling pathways (Lafdil et al., 2009). In
present study, we aim to further characterize the intracellular
pathways that are activated in the Con A-induced model. Using the
immunosuppressive agent CsA, we identify cascades resulting in
liver damage beyond IFN-g involvement after Con A injection.
In contrast to the protective function of the cyclooxygenase
family, 5-LO/FLAP shows hepatotoxicity as an alternative AA
metabolism pathway (Xiao et al., 2015). Our study demonstrates
that through the 5-LO pathway, Cys-LTs levels are signiﬁcantly
increased after Con A treatment, implying that 5-LO upregulation
is responsible for Con A-induced liver inﬂammation. Recent
research has shown that, 5-LO is upregulated due to Con A
induction in mice (Fujita et al., 2015). Extending this, our ﬁndings
indicate that 5-LO is exclusively associated with Cys-LTs generation
in response to Con A stimulation, while FLAP is not involved.
Previous research has also demonstrated that mRNA and miRNA
dysregulation accompanies p38 MAPK-NF-kB pathway activation
during Con A-induced hepatic dysfunction (Xue et al., 2015).
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tion was involved in the underlying 5-LO pathway related
mechanisms. In this study, we identiﬁed several dysregulated
miRNAs, and found that miR-674-5p is a likely candidate for binding
to 5-LO. MiR-674-5p is located in an intergenic region of the mouse
genome GRCm38 (chr2: 117185127–117185226 [+]) (Kozomara and
Grifﬁths-Jones, 2014), and was identiﬁed in the miRNA proﬁles of
mouse (Berezikov et al., 2006; Takada et al., 2006). Since then, miR-
674-5p has been screened out dramatically altered in several studies
by microarray proﬁling (Hufbaueret al., 2011; Nunez et al., 2013), but
to date no follow up gain/loss studies have been conducted. Our in
vivostudyfoundthattransfectionofmiR-674-5pmimictothemouse
cell line Hepa 1–6 lead to a downregulation of 5-LO by IL-6 or TNF-a
co-culture. Notably, attenuated 5-LO expression appeared as early as
1–2 h post challenge, implying the rapid regulating effect of miR-
674-5p on the initiation of cys-LTs-related inﬂammation during IL-6
or TNF-a challenge.
Of the miR-674-5p family, the homologous rno-miR-674-5p
was found to be upregulated in a chronic obstructive pulmonary
disease rat model (Li et al., 2014). Nonetheless, according to the
miRBase (Version 21) (Kozomara and Grifﬁths-Jones, 2014) there is
no counterpart of mmu-miR-674-5p in the human genome. On the
other hand, sequence alignment in our work shows that mammal
5-LO’s share most of the miR-674-5p binding sequence, and the
RNAhybrid analysis shows that the minimum free energy for the
binding of mmu-miR-674-5p/has-5-LO is even lower (33.8 kcal/
mol) than that found in mouse. With these results, we show that
human 5-LO could potentially be regulated by exogenous mmu-
miR-674-mimic in human cell lines HepG2 challenged by IL-6.
Hopefully, the regulation of mmu-miR-674-5p to has-5-LO implies
a possibility in developing exogenous modulators for future
clinical gene therapy. MiR-19a-3p and miR-125b-5p have been
recently reported to downregulate 5-LO (Busch et al., 2015), but
these two microRNAs were not found to be dysregulated in Con A-
induced hepatic dysfunction. Furthermore, in addition to 5-LO,
FLAP is another protein involved in cys-LTs production in the 5-LO
pathway during arachidonic acid metabolism. FLAP expression has
been shown to be downregulated by miR-135a and miR-199a-5p
during hypoxia in human (Gonsalves and Kalra, 2010). In contrast,
our study found no signiﬁcant alteration in FLAP expression during
Con A and/or CsA treatment, suggesting miR-674-5p selectively
targets 5-LO in Con A induced autoimmune hepatitis.
In conclusion, our ﬁndings suggest that miR-674-5p negatively
regulates 5-LO in a post-transcriptional manner in the presence of
IL-6 and TNF-a in Con A induced mouse liver autoimmune reaction
(Fig. 5C). With this in mind, further studies of the miR-674-5p/5-LO
axis represents a compelling avenue towards more effective
treatment of autoimmune liver diseases.
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